Naldemedine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Naldemedine
Naldemedine.svg
Clinical data
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
Formula C32H34N4O6
Molar mass 570.63556 g/mol
3D model (Jmol)

Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist developed by Shionogi which is approved for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. [1] Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects.[2][3] No effects indicative of central opioid withdrawal or impact on the analgesic or mydriatic effects of co-administered opioids have been observed.[2] Since it is chemically related to naltrexone, it is a schedule II controlled substance.[4]

See also[edit]

References[edit]

  1. ^ "FDA Approves Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation - Chemdiv". Chemdiv. 2017-03-27. Retrieved 2017-04-05. 
  2. ^ a b De Sarro, Giovambattista; Kelly S. Sprawls; Egilius L.H. Spierings; Dustin Tran (2012-03-07). "Drugs in Development for Opioid-Induced Constipation" (PDF). In Catto-Smith G., Anthony. Constipation - Causes, Diagnosis and Treatment. p. 7. doi:10.5772/30377. ISBN 978-953-51-0237-3. Retrieved 12 May 2012. 
  3. ^ Shionogi (2009-03-27). "Research and Development at Shionogi (as of March 2009)" (PDF). Retrieved 2012-05-12. 
  4. ^ "FDA Approves Symproic (naldemedine) for the Treatment of Opioid-Induced Constipation - Chemdiv". Chemdiv. 2017-03-27. Retrieved 2017-04-05.